Antibody therapies and methods for treating coronavirus infection
AssigneeTrustees of Boston University
InventorsNelson Ruiz-Opazo, Victoria Herrera
Life of this patent
Estimating the term…
Abstract
Described herein are methods of treating COVID19 from a coronavirus infection, methods of treating a subject having a coronavirus infection, methods of improving a survival rate of a subject having a coronavirus infection, methods of determining prognosis of a subject having a coronavirus infection, methods of preventing or treating organ-dysfunction or multi-organ dysfunction or failure associated with a coronavirus infection, methods of combinational therapy for a subject having a coronavirus infection, methods of reducing microthrombi formation or low flow organ-ischemia associated with a coronavirus infection by administering a DEspR inhibitor.
Claims28
A method of treating a coronavirus infection in a subject,
- the method comprising administering a therapeutically effective amount of a Dual Endothelin/VEGF signal peptide Receptor (DEspR) inhibitor to the subject;
- wherein the DEspR inhibitor is an anti-DEspR antibody reagent or antigen-binding fragment thereof, capable of specifically binding DEspR.
A method of treating a subject having a coronavirus infection in a subject in need thereof, the method comprising administering a Dual Endothelin/VEGF signal peptide Receptor (DEspR) inhibitor to a subject determined to have:
- i) an elevated level or rising level of DEspR+CD11b+ cells, or
- ii) an elevated level of non-resolving neutrophil-monocyte inflammatory amplification that blocks initiation of next step anti-viral adaptive immunity, anti-viral cellular immunity, resolution, or a combination thereof, measured as:
- (1) DEspR+CD11b+ cells,
- (2) a level of hyperinflammation-response marked by elevated ratio DEspR+CD11b+ neutrophils to plasma cytokine storm biomarkers,
- (3) a level of hyperinflammation-response marked by elevated ratio DEspR+CD11b+ neutrophils to plasma oxidative stress biomarkers,
- (4) a level of hyperinflammation-response marked by elevated ratio DEspR+CD11b+ neutrophils to endothelial dysfunction biomarkers, or
- (5) a combination of any of (1), (2), (3), or (4);
- in a sample obtained from the subject,
- wherein an elevated level is elevated as compared to the level in a control subject not having a coronavirus infection;
- and
- wherein the DEspR inhibitor is an anti-DEspR antibody reagent or antigen-binding fragment thereof.
A method of treating organ-dysfunction or multi-organ dysfunction or multi-organ failure associated with a coronavirus infection in a subject in need thereof, the method comprising administering a therapeutically effective amount of a Dual Endothelin/VEGF signal peptide Receptor (DEspR) inhibitor to the subject;
- wherein the DEspR inhibitor is an anti-DEspR antibody reagent or antigen-binding fragment thereof.
A method of combinational therapy for a subject having a coronavirus infection, the method comprising administering to the subject a therapeutic agent or a therapy in combination with a Dual Endothelin/VEGF signal peptide Receptor (DEspR) inhibitor, wherein the therapeutic agent or the therapy alleviates a sign or a symptom associated with the coronavirus infection in the subject;
- and
- wherein the DEspR inhibitor is an anti-DEspR antibody reagent or antigen-binding fragment thereof.
Dependencies are inferred from the claim text.